Skip to main content

Vyalev Side Effects

Generic name: foscarbidopa / foslevodopa

Medically reviewed by Drugs.com. Last updated on Dec 10, 2024.

Note: This document provides detailed information about Vyalev.

Applies to foscarbidopa / foslevodopa: parenteral injection Side Effects associated with foscarbidopa / foslevodopa. Some dosage forms listed on this page may not apply specifically to the brand name Vyalev.

Applies to foscarbidopa / foslevodopa: parenteral injection.

Side effects include:

Most common adverse reactions (≥10% and greater than carbidopa/levodopa): infusion/catheter site reactions, infusion/catheter site infections, hallucinations, dyskinesia.

For healthcare professionals

Applies to foscarbidopa / foslevodopa: subcutaneous solution.

General adverse events

The most frequent adverse reactions occurring in 10% of patients or greater specifically administered this drug included infusion site events, hallucination, fall, anxiety, dyskinesia, depression, and urinary tract infection. Reported adverse events include reactions following exposure to either this drug or a carbidopa/levodopa intestinal gel preparation.

Adverse reactions resulting in discontinuation in 22% of patients were hallucinations, infusion site reactions, and infusion site infections.[Ref]

Cardiovascular

Dermatologic

Gastrointestinal

Genitourinary

Hematologic

Hepatic

Hypersensitivity

Local

Infusion site events, including infusion site reactions (up to 77.6%) and infections (up to 41.4%), were commonly seen with subcutaneous administration in the clinical studies. Most events were mild or moderate in severity. In a few cases, infusion site infections resulted in sepsis requiring hospitalization.[Ref]

Metabolic

Musculoskeletal

Nervous system

Polyneuropathy included peripheral neuropathy, decreased vibratory sense, peripheral sensory neuropathy, sensory disturbance, and sensory loss.[Ref]

Ocular

Oncologic

Other

Psychiatric

Hallucination included visual, auditory, olfactory, tactile, and mixed hallucinations.[Ref]

Renal

Respiratory

See also:

References

1. (2024) "Product Information. Produodopa (foscarbidopa-foslevodopa)." AbbVie Ltd

2. (2024) "Product Information. Vyalev (foscarbidopa-foslevodopa)." AbbVie US LLC

3. (2024) "Product Information. Vyalev 2400/120 (foscarbidopa-foslevodopa)." AbbVie Pty Ltd, Version 1

Further information

Vyalev side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.